Talvey

News

J&J's multiple myeloma duo aces phase 3 trial

Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

J&J says two drugs are better than one in pretreated myeloma

Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.

News

J&J bags first FDA approval for a GPRC5D drug

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat

J&J's multiple myeloma duo aces phase 3 trial

Data could move J&J's Talvey earlier in myeloma therapy

J&J says two drugs are better than one in pretreated myeloma

J&J bags first FDA approval for a GPRC5D drug

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Talvey

Editor's Picks